Want to see BHVN full AI Analyst Report?
BHVN Stock Chart & Stats
$14.32
-$0.33(-2.25%)
At close: 4:00 PM EDT
$14.32
-$0.33(-2.25%)
Day’s Range― - ―
52-Week Range$7.48 - $18.57
Previous CloseN/A
Volume1.72M
Average Volume (3M)3.16M
Market Cap
$2.17B
Enterprise Value$2.27K
Total Cash (Recent Filing)$267.87M
Total Debt (Recent Filing)$292.37M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Nov 17, 2026EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.64
Shares Outstanding151,043,780
10 Day Avg. Volume1,832,109
30 Day Avg. Volume3,164,803
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)23.33
Price to Sales (P/S)0.00
P/FCF Ratio-1.99
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$18.78Price Target Upside31.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.18
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal Clinical Progress For OpakalimRobust proof-of-concept and a clear path into pivotal Phase 2/3 in H2 2026 materially de-risks a lead program. Durable impact: a successful pivotal readout would create a commercialization pathway, validate R&D strategy, and attract partners or licensing opportunities.
Proprietary MoDE And TRAP PlatformsPlatform-level technology that selectively degrades extracellular disease proteins offers a structural competitive advantage. If validated across multiple programs, it enables pipeline diversification, recurring partner deals, and longer-term value creation beyond any single asset.
Strengthened Scientific Leadership And GovernanceTargeted leadership changes and promotions enhance discovery execution and external collaborations. Strengthening discovery leadership and governance is a durable improvement that can raise R&D productivity, improve partner interactions, and reduce program execution risk over time.
Bears Say
Heavy And Accelerating Cash BurnSustained ~-$500M annual cash outflows materially shortens runway and forces regular access to capital. Over the medium term this increases dilution risk and constrains strategic flexibility, making long-term planning contingent on financing or near-term partnering/asset milestones.
Severely Weakened Balance Sheet And High LeverageExtremely elevated leverage and minimal equity cushion raise refinancing and covenant risk, reducing financial flexibility. This structural capital weakness worsens negotiation power with partners and increases the likelihood of dilutive financings if clinical timelines slip.
No Revenue; Large Ongoing Operating LossesAs a development-stage biotech with no product revenue, sustainability hinges on successful trials or external funding. Persistent, sizable losses mean continued dependence on markets or partners, amplifying execution and financing risk over the coming months.
Biohaven Ltd. News
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $7.48 and its highest was $18.57 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Biohaven Ltd.’s market cap is $2.17B.
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is Nov 17, 2026 which is in 95 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on Aug 10, 2026. The company reported -$0.91 earnings per share for the quarter, missing the consensus estimate of -$0.761 by -$0.149.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -0.76.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 151,043,780 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$0.91 in its last earnings report, missing expectations of -$0.761. Following the earnings report the stock price went down -0.344%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Currently, no hedge funds are holding shares in BHVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biohaven Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.78 (31.13% Upside)
$18.78 (31.13% Upside)
Blogger Sentiment
Bullish
BHVN Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 757.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 8.2%
Last 30 Days ▼ 8.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-32.64%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
BHVN Stock 12 Month Forecast
Average Price Target
$18.78
▲(31.13% Upside)
Technical Analysis
Ownership Overview
10.74% Insiders
11.94% Mutual Funds
6.02% Other Institutional Investors
63.01% Public Companies and
Individual Investors